W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

Transparency Council

09 September, 2022

Opinion of the Transparency Council – Health policy programme for the prevention of meningococcal infections for children in the Municipality of Kielce

09 September, 2022

Opinion of the Transparency Council – health policy programme on infertility treatment (district olkuski)

09 September, 2022

Opinion of the Transparency Council – health policy programme on in vitro fertilisation (Jelenia Góra)

09 September, 2022

Position of the Transparency Council – Tript-OH (oksytryptan)

08 September, 2022

The Meeting of the Transparency Council No. 36/2022 of 12.09.2022

30 August, 2022

Position of the Transparency Council – Renastep

30 August, 2022

Opinion of the Transparency Council – entecavirum and tenofovirum disoproxilum

30 August, 2022

Opinion of the Transparency Council – health policy programme in the field of perinatal care (Municipality of Stare Babice)

25 August, 2022

The Meeting of the Transparency Council No. 35/2022 of 05.09.2022

24 August, 2022

Position of the Transparency Council – Milupa Basic-P

24 August, 2022

Position of the Transparency Council – Ospolot (sultiam)

24 August, 2022

Position of the Transparency Council – Jardiance (empagliflozyna)

24 August, 2022

Position of the Transparency Council – Yervoy (ipilimumab)

24 August, 2022

Position of the Transparency Council – Opdivo (niwolumab)

24 August, 2022

Position of the Transparency Council – Tremfya (guselkumabum)

24 August, 2022

Opinion of the Transparency Council – methotrexatum

24 August, 2022

Opinion of the Transparency Council – cyclophosphamidum

24 August, 2022

Opinion of the Transparency Council – azathioprinum

24 August, 2022

Position of the Transparency Council – Empliciti (elotuzumab)

24 August, 2022

Position of the Transparency Council – Ontozry (cenobamat)

24 August, 2022

Opinion of the Transparency Council – recommended medical technologies, actions to be carried out under health policy programmes and the implementation conditions for the glaucoma prevention programmes

24 August, 2022

Position of the Transparency Council – qualifying of health care services financed from the entrusted budget and provided on the order of a primary care physician

22 August, 2022

The Meeting of the Transparency Council No. 34/2022 of 29.08.2022

17 August, 2022

The Meeting of the Transparency Council No. 33/2022 of 22.08.2022

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑